Navigation Links
Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
Date:12/3/2010

n order to deliver new options that target specific hematologic abnormalities and mutations, it is important to understand the molecular subtypes and genetic variations associated with hematologic cancers. Pfizer Oncology has biologics and small molecules in clinical development across a number of hematologic malignancies.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. Pfizer Oncology has biologics and small molecules in clinical development and more than 100 clinical trials underway. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.   For more information please visit www.Pfizer.com.  

DISCLOSURE NOTICE: The information contained in this release is as of December 3, 2010. Pfizer assumes no obligation to update  forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about certain potential indications for bosutinib, an oncology product candidate, including their potential benefits and the planned timing of regulatory submissions for such indications, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including with regard to the pending 24-month dat
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
2. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
3. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
6. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
7. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
8. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
9. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
10. Biocon and Pfizer Enter Into Global Commercialization Agreement
11. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015 Braeburn ... its current therapeutic focus beyond addiction and ... psychiatric disorders. Braeburn has acquired an implantable, ... antipsychotic risperidone for treatment of schizophrenia from ... acquires global rights to other potential applications ...
(Date:5/1/2015)... -- Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) ... 31, 2015, as well as general business updates. Due ... will be held. Key Highlights , ... increased to $206 million from $119 million for the ... ® (ibrutinib) net product revenue of $247 million ...
(Date:5/1/2015)... May 1, 2015  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... for the third quarter fiscal year 2015 on ... a conference call that same day, Thursday, May ...
Breaking Medicine Technology:Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 27Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 28Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 29Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 30Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 31Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 32Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 33
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that ... approvals necessary to complete the acquisition of Paddock ... of generic Rx pharmaceuticals and OTC specialty products. ... C. Papa stated, "We are looking forward to ...
... Corporation ("Unilife" or the "Company") (NASDAQ: UNIS ... completed the validation phase of the Unifill® ready-to-fill (prefilled) ... in the industrialization process for the Unifill syringe. ... completion of all validation tests associated with the Unifill ...
Cached Medicine Technology:Perrigo Provides Update on Acquisition of Paddock Labs 2Perrigo Provides Update on Acquisition of Paddock Labs 3Unilife Successfully Completes Industrialization of Unifill Syringe 2Unilife Successfully Completes Industrialization of Unifill Syringe 3Unilife Successfully Completes Industrialization of Unifill Syringe 4
(Date:5/2/2015)... May 03, 2015 As one of ... the prestigious Safety and Health Achievement and Recognition Program ... to be chosen by the Illinois Department of Labor ... achieved and maintained SHARP certification by the Occupational Safety ... as Essentra has continued to meet or exceed all ...
(Date:5/2/2015)... May 02, 2015 ProText Kinetic 2 is ... in Final Cut Pro X. ProText Kinetic 2 features ... Final Cut Pro X . Easily create interactive ... Pixel Film Studios' ProText Kinetic 2. , Using ProText Kinetic ... staggering two ProText Kinetic presets in the FCPX timeline. ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
(Date:5/2/2015)... With the success that Veatch Dental Consulting has had ... Miranda and Alex Shields to the team. With Neida and ... of combined experience working with dentists to ensure their success. ... 8 years. She was certified as dental assistant from ... attitude and showing the importance of oral hygiene to patients, ...
(Date:5/1/2015)... Jusuru International has been awarded the ... of its flagship nutritional supplement, Liquid BioCell™ Life, and ... name, new logo, new packaging, new products, and new ... to identify and promote programs that serve as examples ... congratulates Jusuru International for their outstanding accomplishments and contributions ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... the fact that uncomplicated twin pregnancies may be more ... ,Researchers of Imperial College London report that normal monochorionic ... deaths. In monochorionic diamniotic twin pregnancy, the twin fetuses ... and often are the most common form of twin ...
... that teenage girls living in temperate countries or colder regions ... they took supplements of Vitamin D in the winter months ... sun is important for formation of the active component of ... would help to strengthen bones for later years. The researchers ...
... According to the article published in The Journal of ... of antibiotics for // acute uncomplicated lower respiratory tract ... is a common complaint in the out patient departments ... is treated. ,The randomized controlled trial was ...
... have identified an enzyme’s new role in aiding joint ... called cathepsin G can regulate the ability of the ... process of inflammatory conditions that can lead to arthritis. ... that can lead to damage of the tissue and ...
... reaction to a common water pollutant called arsenic may not ... out to a gene called CYT19 in people, particularly in ... metal called arsenic. ,Arsenic exposure had long been associated ... bladder, circulatory problems, and neurological disorders. It can enter the ...
... vehicles in the world could run using a pollution free ... from Stanford are just working towards this solution to look ... fuel cells and the hydrogen would reacts with oxygen to ... combustion mechanism and this would be pollution free. A similar ...
Cached Medicine News:Health News:Vitamin D Supplement in Teenage Girls essential in Winter months 2Health News:Antibiotics for acute uncomplicated lower respiratory tract infection 2Health News:Pollution Free Hydrogen based fuel for Energy 2Health News:Pollution Free Hydrogen based fuel for Energy 3
Used to negotiate spiral folds of the cystic duct and the lumen of the common duct. TFE coating reduces surface tension. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
... biopsy with the MAMMOTOME® HH ... minimally invasive procedure using ultrasound ... computer-generated images to locate breast ... pinpoint and map the area ...
... temporary wound support. Especially suitable for ... support material is desired and containment ... Predictable absorption. Polyglactin 910 has been ... nonpyrogenic. ,VICRYL (polyglactin 910) knitted mesh ...
Medicine Products: